Use of a peptide fragment of CD44v6 in the treatment of ophthalmic diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8883738
SERIAL NO

13713594

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • KARLSRUHER INSTITUT FUER TECHNOLOGIE;KARISRUHER INSITUT FÜR TECHNOLOGIE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Matzke, Alexandra Dettenheim, DE 8 5
Orian-Rousseau, Véronique Rittershofen, FR 6 9
Ponta, Helmut Graben-Neudorf, DE 17 43
Tremmel, Martina Weinheim, DE 2 5

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 11, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00